ReviewPharmaceuticals (Basel, Switzerland)2019
Antiviral Agents in Development for Zika Virus Infections.
Review in Pharmaceuticals (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 73 citations in OpenAlex.
- Article
- Antiviral and anti-inflammatory effects of Tabamide A derivative, TA25, against human rhinovirus and multiple zoonotic viruses in vitro and in silico.Scientific reports · 2026Article
- Antiviral Activity of Ethyl Gallate Against Zika Virus: In Vitro and In Silico Studies.International journal of molecular sciences · 2025Article
- Arboviruses: the hidden danger of the tropics.Archives of virology · 2025Review
- Dengue Virus Inhibitors as Potential Broad-Spectrum Flavivirus Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Antiviral activity of eicosapentaenoic acid against zika virus and other enveloped viruses.Frontiers in pharmacology · 2025Article
- An Overview of Zika Virus and Zika Virus Induced Neuropathies.International journal of molecular sciences · 2024Review
- Envelope Protein-Targeting Zika Virus Entry Inhibitors.International journal of molecular sciences · 2024Review
- Employing Machine Learning-Based QSAR for Targeting Zika Virus NS3 Protease: Molecular Insights and Inhibitor Discovery.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Evaluation of Thiazolidine Derivatives with Potential Anti-ZIKV Activity.Current topics in medicinal chemistry · 2024Article
- Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors.Journal of inflammation research · 2024Review
- Dapoxetine, a Selective Serotonin Reuptake Inhibitor, Suppresses Zika Virus Infection In Vitro.Molecules (Basel, Switzerland) · 2023Article
- Peptidomimetic Oligomers Targeting Membrane Phosphatidylserine Exhibit Broad Antiviral Activity.ACS infectious diseases · 2023Article
- Antiviral Activity of Quercetin Hydrate against Zika Virus.International journal of molecular sciences · 2023Article
- Article
- Neural circuits mediating circulating interleukin-1β-evoked fever in the absence of prostaglandin E2 production.Brain, behavior, and immunity · 2022Article
- Pathogenesis and Manifestations of Zika Virus-Associated Ocular Diseases.Tropical medicine and infectious disease · 2022Review
- Zika M-A Potential Viroporin: Mutational Study and Drug Repurposing.Biomedicines · 2022Article
- Antiviral effects of azithromycin: A narrative review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Searching for plant-derived antivirals against dengue virus and Zika virus.Virology journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 1947, Zika virus (ZIKV), a mosquito-borne flavivirus was identified in Uganda and subsequently spread to Asia and the Pacific regions. In 2015, it was introduced in Brazil causing an important social and sanitary alarm due to its increased virulence and rapid dissemination. Importantly, ZIKV infections have been associated with severe neurological complications such as Guillain-Barré syndrome and microcephaly in fetuses and newborns. Although enormous efforts were made by investigators in the development of effective countermeasures against ZIKV, there is still no approved specific antiviral drug for the treatment of ZIKV infections. Herein, we review several anti ZIKV candidates including drugs targeting both the virus (structural proteins and enzymes) and cellular elements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.